JNJ

Best Dividend Aristocrats For November 2025

Discover why select S&P 500 Dividend Aristocrats may outperform in 2025. Explore top picks and growth insights.

Appointment of Yves Decadt as Member of Poxel’s Board of Directors

LYON, France, October 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.

AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.

FEATURE AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.

AbbVie: Why Q3 Confirms Its Immunology Dominance

AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.

The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage

Broadcom, Johnson & Johnson, and Palantir headline Zacks' latest analyst picks, with AI growth, pharma innovation, and defense tech momentum driving their outlooks.